PDE File Medication Utilization; Medication Possession Ratio. Kyoungrae Jung, Ph.D. Assistant Professor Penn State University

Similar documents
Sujita Narayan. Research in Pharmacoepidemiology National School of Pharmacy, University of Otago

Medication Adherence

Part D PDE Data and the Opioid Epidemic

Getting Hypertension Under Control

Understanding Your Patient Care Opportunity Report (PCOR)

USING MTM TO IMPROVE STAR RATINGS : CASE STUDIES

Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophreniavhe_

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.

HEDIS 2018 Medications List Directory User Manual

Mail Service Pharmacy

Pharmacy Benefit Management

Drug Therapy Management

KEY BEHAVIORAL MEASURES

ENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS

Your Prescription Card. Your guide for savings.

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

Key Behavioral Health Measures (18 Years and Older)

Performance Outcomes: Measure & Metric Details

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Designing Pharmacy Practice Research

Improve the Adherence, Save the Life

Proposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

PATIENT-IMPACT SCORECARD

2017 URAC PHARMACY BENEFIT MANAGEMENT PERFORMANCE MEASUREMENT: AGGREGATE SUMMARY PERFORMANCE REPORT

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.

MEASURE STEWARD Pharmacy Quality Alliance (PQA) D ATA SOURCE Enrollment; U R A C DOMAIN Engagement & Experience of Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Jae Jin An, Ph.D. Michael B. Nichol, Ph.D.

Disease Management. Measures At A Glance

ADHERTENCE AND COMPLIANCE TO TREATMENTS

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Medicare Star Ratings and the Shift to Quality- Based Payment Models. David Nau, RPh, PhD, FAPhA PQS President

See reverse side for important facts about how to save on your prescriptions.

Cost-Effective Process to Improve Drug Adherence for Medicare 5-Star

Medicare Part D Overutilization Monitoring System

The Self-Medication Assessment Tool (SMAT) Training Program

A&M Care Prescription Drug Program Express Scripts Holding Company. All Rights Reserved.

Clinical Safety & Effectiveness Cohort 19 Team #13. Improving Adherence to Antidepressant Medications in the Acute Treatment Phase

Disease Management. Measures At A Glance

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

Commercial Business Medical Cost Target

Changes to Texas Medicaid Hearing Services Benefits to Accompany PACT Transition

Patient-Centered Primary Care Scorecard Measure Specifications

Pharmacy Technician Course

16 th Annual IHA Stakeholders Meeting Session 2C

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC

KEY BEHAVIORAL MEASURES

Rethink. Adherence. David D. Pope, PharmD, CDE Editor-in-Chief, CreativePharmacist.com Brands

Your Prescription Card. Your guide for savings.

A Bad Outcome. Drugs don t work in patients who don t take them. Does Compliance Really Matter? Why Should I Care about This?

Arkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual

Commercial Business Medical Cost Target

To Take or Not To Take?

Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care

ANALYSIS OF KENTUCKY MEDICAID MANAGED CARE VERSUS FEE-FOR- SERVICE SYSTEMS: MEDICATION ADHERENCE IN PATIENTS WITH PREVALENT CHRONIC DISEASES

STARS SYSTEM 5 CATEGORIES

Patient-Centered Primary Care Scorecard Measures

Potentially Inappropriate Medications in Elderly Patients: Prevalence at Admission and Changes During Hospital Stay

PCMH 2018 Enrollment and Update August 25, 2017

USING PHARMACY CLAIMS DATA TO EVALUATE ADHERENCE AND PERSISTENCE WITH PRESCRIBED MEDICATIONS IN PATIENTS WITH DIABETES MELLITUS

Pharmacy Audit Recovery Guidelines

Trainers Guide. Role of Dispensers in Promoting Rational Drug Use

Quality ID #195 (NQF 0507): Radiology: Stenosis Measurement in Carotid Imaging Reports National Quality Strategy Domain: Effective Clinical Care

TOP 5 DRUGS.. TO AVOID IN THE ELDERLY

Exploring Temporal Patterns in Hypertensive Drug Therapy

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Improved Transparency in Key Operational Decisions in Real World Evidence

Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction

Guideline for the Rational Use of Controlled Drugs

Hypertension and the Challenge of Adherence. Geneva Clark Briggs, Pharm.D., BCPS

Understanding and Addressing Problematic Medication Adherence

ZERO SUICIDE DATA ELEMENTS WORKSHEET

Issues for Part D Compliance

Methodological Considerations in Estimating Adherence and Persistence for a Long-Acting Injectable Medication

EXAMPLE ONLY. RxBIN Issuer (80840) ID NAME Drew Zehnder. Houston Methodist 6565 Fannin Street, GB164 Houston, TX 77030

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Disclosure. Learning Objectives 6/4/2014. Medication Adherence: Challenges and Opportunities

LRE Executive Dashboard Integrated Care Delivery Platform (ICDP)

General Providers. Tamper-Resistant Prescription Requirements

RECEIVING YOUR PERMANENT

The practice of using multiple medications occurs in many

Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at:

Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review

Section 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for

ARE MEDICATION ADHERENCE QUALITY INDICATORS ASSOCIATED WITH CLINICAL OUTCOMES? A DISSERTATION SUBMITTED ON THE TENTH DAY OF AUGUST 2012

Alabama Medicaid Pharmacy Override

Capital Health Plan CMS Star Ratings Strategies for Improvement

PRSB e-discharge summary phase 2 Medications and medical devices information model

Quality ID #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

STATE OF NEW JERSEY OFFICE OF THE STATE COMPTROLLER MEDICAID FRAUD DIVISION

STEP THERAPY IN MEDICARE PART D

NCQA that the exclusion still applies.

Commercial Business Measurement Period Handbook For Patient-Centered Primary Care

EVALUATION OF USE OF BELIMUMAB IN CLINICAL PRACTICE SETTINGS PATIENT CASE RECORD FORM PHASE II, MONTH PATIENT FOLLOW-UP

Anesthesia Reimbursement

Update on New RCHC Relevant and BridgeIT Reports. Redwood Community Health Coalition Data Group Webinar November 13, 2018 By Ben Fouts, Data Analyst

Transcription:

PDE File Medication Utilization; Medication Possession Ratio Kyoungrae Jung, Ph.D. Assistant Professor Penn State University

Outline PDE variables related to medication utilization Measures of medication utilization based on PDE records 2

PDE Variables Related to Medication Utilization (I) Product Service ID (PROD_SRVC_ID) Identifies the dispensed drug using NDC Variables associated with Product Service ID Brand Name (BN) Generic Name (GNN) Need to be spelled correctly 3

Identifying Therapeutic Class If you are interested in examining a therapeutic class (e.g., anti-diabetics, anti-hypertensives, statins etc), identify all NDCs for the therapeutic class of interest From a proprietary data-base (e.g., Medi-Span) Use Product Service ID (PROD_SRVC_ID) If you know generic names of drugs, you can use Generic Name (GNN). Spell out correctly 4

PDE Variables Related to Medication Utilization (II) Prescription Service Date (SRVC_DT) Prescription initiation date Prescription Days Supply (DAYS_SUPLY_NUM) Prescription amount 5

Prescription Days Supply Key variable to construct medication adherence measures Median/Mode: 30 days Distributions: 30 days: 66.85% 1 29 days: 19.9% 31-100 days: 13.24% 101-180 days: 0.01% Records with 0 or >180 may be found (<0.01%) 6

Measures of Medication Utilization 7

Measures of Medication Utilization 1. Whether a recommended medication is used Can be used for a population with a specific condition» Requires information on diagnosis» Medicare Part A/B claims data are needed to construct this measure based on PDE records 8

Measures of Medication Utilization 2. Medication adherence Captures whether a patient takes a prescribed medication according to a schedule Various measures have been used % of time with Rx vs. % of time without Rx Specified time period vs. during refill intervals 9

PDE Data Fields to Construct Medication Utilization Measures Variable Name Description Why Needed PROD_SRV_ID Product Service ID Identify Rx or Rx class SRVC_DT Rx fill date Initiation (fill) dates DAYS_SUPLY_NUM Rx days supplied Amount of Rx 10

Measures of Medication Utilization Based on PDE Data Measure acquisition of medications not consumption Cannot measure timing of taking medications Good for long-term follow-up 11

Measures of Medication Adherence Measure Description Terminology Measures of medication availability Proportion of days supply during a specified time period or over a period of refill intervals -Medication Possession Ratio (MPR) -Proportion of Days Covered (PDC) -Medication Refill Adherence (MRA) -Refill Compliance Rate (RCR) -Continuous Measure of Medication Acquisition (CMA) -Compliance rate (CR) -Adherence Ratio Hess, et al. Ann Pharm July/Aug 2006 Andrade et al. Pharm. and Drug Safety, 2006 12

Medication Possession Ratio (MPR) Most commonly used measure of adherence Proportion of days supply during a given time period Can be defined differently depending on how a time period is specified 13

Medication Possession Ratio (MPR) Two main definitions: 1) MPR 2) MPRm: MPR modified 14

Specifying a Time Period Fixed follow-up period (e.g., 1 year) With a fixed time period, numerator only (duration of therapy) can be used as an adherence measure Evaluation period From the first fill to the end of the follow-up period Denominator varies by patient 15

Does Denominator Matter? MPR vs. MPRm Detail of Each Fill (4/19/09-4/18/10) Fill Day Days Supplied Days in Interval Adherence Value of Different Measures April 27 35 26 MPR: 0.323 May 23 35 48 MPRm: 0.90 July 10 8 4 July 14 30 42 August 25 10 237 TOTALS 118 357 Source: Hess, et al. Ann Pharm July/Aug 2006 (Modified Table 1) 16

Choosing an Adherence Measure Study goal and relative advantage (Andrade et al., 2006) Whether therapy is generally prescribed for a defined period only or for a life-long condition should determine how to treat early termination (e.g., MPR vs. MPRm) Dichotomous measure may be used if an appropriate cut-off (of adherence) can be justified 17

Choosing an Adherence Measure Data availability and cost MPR and related measures are easy to calculate (& interpret) 18

Issues to Consider When Constructing Adherence Measures Over-supply Medications provided during hospital admissions Taking multiple medications for a given condition - Metformin & sulfonylurea for diabetes - Diuretics & ACE inhibitors for hypertension 19

Example of Excessive Supply Detail of Each Fill (6/16/09-6/15/10) Fill Day Days Supplied Days in Interval June 19 35 21 July 10 35 35 August 14 30 30 September 13 30 30 October 13 30 31 November 13 30 35 December 18 30 15 January 2 30 38 February 9 30 26 March 7 30 5 March 12 30 58 May 9 30 36 June 14 30 1 TOTALS 400 362 Hess, et al. Ann Pharm July/Aug 2006 20

Handling Hospitalization and SNF Stay Medications provided during hospital admit Exclude hospitalized subjects Assume all Rx provided while in hospital, so add days to supply (numerator) or reduce interval (denominator) 21

Handling Hospital/SNF Stay: Example 280 days of Rx in 1 yr w/ 20 day hospital stay Ignore: 280/365=0.767 Add to days supply: (280+20)/365=0.822 Reduce total interval: 280/(365-20)=0.812 How addressed potentially changes outcome if adherence dichotomized (=1 if 80%) 22

Other Decisions: Multiple Meds for a Given Condition Create Rx-specific adherence & (unweighted) average Benefits: Summarizes overall adherence, simpler model Costs: Potentially misrepresents adherence of each Rx if vastly different 23

Other Decisions: Multiple Meds for a Given Condition Create Rx-specific adherence & model separately Benefits: Allows adherence to each Rx to be represented Costs: More complicated modeling 24

Other Decisions: Timing Measure adherence by year or by month? Person-year» Benefits: Simpler model if one year of data» Costs: May miss important within-year changes Person-month» Benefits: reflect realistic variation within a year» Costs: More complicated modeling 25